During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Longevity research has propelled the scientific community to concentrate on interventions that do more than simply add years ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

In my opinion, daratumumab can improve asymptomatic laboratory and imaging findings, but morbidity remains very low with modern observation ... who are currently CD38 naive at the time of first ...

The team confirmed that the addition of an anti-CD38 monoclonal antibody to a triplet ... primary imaging with whole-body low-dose computed tomography has replaced the skeletal survey because ...

The stock has rebounded since the earnings report, but it was under pressure since my previous update as investors and traders contemplate the fate of GEN3014, the next-generation CD38 HexaBody on ...

Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ETCompany ParticipantsCourtney Dugan - Head-IRMichael Rossi ...